Company: QXO-PB
Filing Date: 2025-06-25
Form Type: 424B5
Source: 0001104659-25-062233
Chunk: 17

Company: QXO, Inc.
Filing Date: 2025-06-25
Form: 424B5
Chunk 17
---
 Loan Facility”), and (c) entry into a $2,000.0 million senior secured asset-based facility (the “ABL Facility”) and incurrence of $400.0 million of indebtedness under the ABL Facility and, in each case, the application of the net proceeds therefrom to pay a portion of the consideration for the Beacon Acquisition, to refinance certain indebtedness in connection with the Beacon Acquisition and to pay related fees and expenses; (iii) the consummation of the Company’s private placement of approximately 67.5 million shares of our Common Stock, at a purchase price of $12.30 per share, and the application of the net proceeds to pay a portion of the consideration for the Beacon Acquisition and to pay fees and expenses related to the Transactions; (iv) the consummation of the Beacon Acquisition and (v) the consummation of the May 2025 Equity Offerings and the application of $1.4 billion of the net proceeds to repay indebtedness outstanding under the Term Loan Facility. We have incorporated by reference pro forma financial information that gives effect to the Transactions (assuming $500 million gross proceeds from the May 2025 Common Stock Offering and $500 million gross proceeds from the May 2025 Depositary Shares Offering) but does not give effect to this offering.

#### Corporate Information
Our principal executive offices are located at Five American Lane, Greenwich, Connecticut 06831. Our telephone number is (888) 998-6000. Our website is www.qxo.com. The information on our website is not incorporated by reference into this prospectus supplement or the accompanying prospectus (except for SEC reports that are expressly incorporated by reference herein).

<div align='center'>S-6</div>

TABLE OF CONTENTS

### THE OFFERING
Issuer

QXO, Inc.

Securities offered

$2,000,000,000 of shares of Common Stock.

Option to purchase additional shares of Common Stock

We have granted the underwriters an option to purchase up to $300,000,000 of additional shares of Common Stock at the public offering price less underwriting discounts and commissions. The underwriters may exercise this option at any time within 30 days from the date of this prospectus supplement.

Shares of Common Stock to be outstanding after this 
 offering

shares of Common Stock (or shares of Common Stock if the underwriters exercise in full their option to purchase additional shares).

Use of proceeds

We expect to receive net proceeds from this offering of approximately $ (or